+1 (502) 904-2126   One Westbrook Corporate Center, Suite 300, Westchester, IL 60154, USA   Site Map
ISSN: 2574 -1241

Impact Factor : 0.548

  Submit Manuscript

Research ArticleOpen Access

Glioblastoma and Glioblastoma with Oligodendroglial Component: a Histological and Prognostic Overview Runing Head: pathology and GBM and GBMO

Volume 9 - Issue 4

Ravindra Pramod Deshpande1, Chandrasekhar YBVK2, Manas Panigrahi2, I Satish Rao3 and Phanithi Prakash Babu*1

  • Author Information Open or Close
    • 1Department of Biotechnology and Bioinformatics, School of Life Sciences, University of Hyderabad, India
    • 2Department of Neurosurgery, Krishna Institute of Medical Sciences, Secunderabad, India
    • 3Department of pathology, Krishna Institute of Medical Sciences, Secunderabad, India

    *Corresponding author: P Prakash Babu, Department of Biotechnology and Bioinformatics, School of Life Sciences, University of Hyderabad, Hyderabad-500046. Telangana state, India

Received: September 25, 2018;   Published: October 04, 2018

DOI: 10.26717/BJSTR.2018.09.001828

Full Text PDF

To view the Full Article   Peer-reviewed Article PDF


Glioblastoma (GBM- GIV astrocytoma) represents the most noted neoplasms of the brain usually reported with dismal prognosis. The term glioblastoma with oligodendroglial component (GBMO) represents the present of oligodendroglial foci in glioblastoma tumors. GBMOs are usually represented with better therapeutic response and concomitant prognostic outcome. We have observed nearly 610 cases of various pathologic grades of astrocytoma from 2009 to 2014 and found the oligodendroglial component among the 40 cases. Nearly in all the cases of GBM and GBMOs received complete resection and was followed by standard therapeutic regime of radiotherapy and chemotherapy with temozolomide. The survival pattern was observed in patients diagnosed with GBM and GBMO. We have looked for the presence of MIB1, p53 and necrosis pattern in selected GBMO sub group. We observe nearly 54% of GBMOs stained positive with p53. Necrosis and MIB1 was observed in most of the GBMO cases. These was statistically significant difference among survival of glioblastoma patients’ and GBMOs. Glioblastoma multiformae patients with oligodendroglial component was observed to have median survival of 16 months while with GBM it was observed to be 12 months. GBMO were found to have significantly longer survival than glioblastoma patients’ and respond well to chemo and radiotherapy.

Keywords: Glioblastoma; GBMO; P53; Mib1; Survival

Abbreviations: GBMO: Glioblastoma with Oligodendroglial Component; WHO: World Health Organization; ICE: Institutional Ethics Committee; KFRC: KIMS Foundation Research Centre

Abstract | Introduction | Materials and Methods| Discussion| Funding| Acknowledgements| Ethical approval| Informed consent| References|